Cerus Reports Strong Q1 Earnings and Raises 2026 Revenue Guidance
Cerus reported first-quarter product revenue of $53.7 million, a 24% year-over-year increase driven by its INTERCEPT platelet franchise and IFC business growth in the U.S. The company raised full-year product revenue guidance to $227–$231 million with an updated IFC range of $22–$24 million.
Tickers: $CERS
Topics: guidance update IFC growth INTERCEPT platelet franchise product revenue regulatory milestones